OCT 7 - 2005

K050985

510(k) Summary

According to the requirements of 21 CFR.807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

1. Submitter Name, Address, Contact	All Medicus., Co. Ltd. #7106, Dong-il Techno Town 7th., 823, Gwanyang 2-dong, Dongan-gu, Anyang. Gyeonggi-do, 431-062, Korea Phone : (82) 31-425-8288 Fax : (82) 31-422-8589 Contact Person : Mr. Chang, Je Young
2. Date Prepared	Mar 07, 2005
3. Device Name	Propriety name : GlucoDr™ SuperSensor System Common name : Blood glucose monitoring system Classification name : Glucose Test System (21 CFR Section 862.1345, Product Code : LFR)
4. Predicate Device	We claim substantial equivalence to the Roche Diagnostics Corporation, Accu-Chek Advantage System. (K032552)
5. Device Description	The GlucoDr™ SuperSensor system consists of the GlucoDr™ SuperSensor Test Meter, GlucoDr™ SuperSensor Test strips and GlucoDr™ SuperSensor control solution.

The GlucoDr™ SuperSensor system is based on measurement of electrical currents caused by the reaction of glucose with the regents on the glod electrode strip. Glucose in the sample reacts with glucose dehydrogenase and mediators. This reaction creates electrical currents. The subsequent electrical currents is proportional to the glucose concentration in the blood and converted to the equivalent glucose concentration by the algorithm programmed in the GlucoDr™ SuperSensor test meter.

6. Intended use

The GlucoDr™ SuperSensor system is intended for in vitro diagnostic use (i.e., for external use only) for quantitative measurement of glucose in capillary, venous, and arterial whole blood.

7. Comparison to Predicate Device

The GlucoDr™ SuperSensor system has equivalent technological characteristics as the Accu-Chek Advantage System. The GlucoDr™ SuperSensor system also has the same intended use as the Accu-Chek Advantage System.

8. Conclusion

The GlucoDr™ SuperSensor system is substantially equivalent to the predicate device system.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

OCT 7 - 2005

Mr. Je Young Chang
All Medicus., Co.Ltd.
7106, Dong-il Techno Town 7th
823, Gwanyang 2-dong, Dongan-gu, Anyang
Gyeonggi-do, 431-062, Korea

Re: k050985
Trade/Device Name: GlucoDr™SuperSensor
Regulation Number: 21 CFR 862.1345
Regulation Name: Glucose test system
Regulatory Class: Class II
Product Code: NBW, LFR, JJX
Dated: September 30, 2005
Received: October 4, 2005

Dear Mr. Chang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Carol C. Benson

Carol C. Benson, M.A.
Acting Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

Revised

Indications for Use

510(k) Number (if known): k050985

Device Name: GlucoDr™ SuperSensor

Indications For Use:

The GlucoDr™ SuperSensor system is intended for in vitro diagnostic use (i. e., for external use only) for quantitative measurement of glucose in venous whole blood and capillary whole blood from the fingertip.

The GlucoDr™ SuperSensor system may be used by healthcare professionals or for self testing by diabetic lay users in the home.

The GlucoDr™ SuperSensor system is not intended for the diagnosis of or screening for diabetes mellitus.

The GlucoDr™ SuperSensor system is not intended for use on neonates.

Prescription Use ✓ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use V (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) k050985